(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.85%.
Lantern Pharma's earnings in 2026 is -$18,920,421.On average, 3 Wall Street analysts forecast LTRN's earnings for 2026 to be -$21,789,493, with the lowest LTRN earnings forecast at -$20,935,003, and the highest LTRN earnings forecast at -$22,430,360. On average, 3 Wall Street analysts forecast LTRN's earnings for 2027 to be -$23,044,385, with the lowest LTRN earnings forecast at -$22,140,684, and the highest LTRN earnings forecast at -$23,722,161.
In 2028, LTRN is forecast to generate -$24,071,115 in earnings, with the lowest earnings forecast at -$23,127,150 and the highest earnings forecast at -$24,779,089.